Financial News
Headline News about Crispr Therapeutics Ag
![](https://g.foolcdn.com/editorial/images/762836/gettyimages-998452928.jpg)
![](https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2.jpg)
![](https://g.foolcdn.com/editorial/images/761459/patient-sitting-on-hospital-bed.jpg)
![](https://g.foolcdn.com/editorial/images/761794/two-scientists-review-data-in-lab-bench.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://g.foolcdn.com/editorial/images/761254/person-delivering-a-presentation-at-a-meeting.jpg)
![](https://g.foolcdn.com/editorial/images/761747/gettyimages-476196983.jpg)
![](https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg)
![](https://g.foolcdn.com/editorial/images/761796/scientist-studies-test-tube.jpg)
![](https://g.foolcdn.com/editorial/images/760860/two-investors-look-at-figures.jpg)
![](https://g.foolcdn.com/editorial/images/761822/dna-on-monitor-scientists.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/shutterstock_1926453779-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2024/Cathie-Wood-Photo-courtesy-Benzinga-YouT.jpeg?width=1200&height=800&fit=crop)
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
January 17, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/Gene-therapy.jpeg?width=1200&height=800&fit=crop)
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2024/cathie-wood-bz-ark_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2023/11/Stock-crispr-dna-03-adobe.jpg)
![](https://g.foolcdn.com/editorial/images/761175/gettyimages-1214328228.jpg)
![](https://g.foolcdn.com/editorial/images/761374/dna-genetic-sequencing-biotech.jpg)
![](https://g.foolcdn.com/editorial/images/761232/biotech-researcher.jpg)
![](https://g.foolcdn.com/editorial/images/761086/smart-investor-looking-for-stocks-to-buy-getty.jpg)
![](https://g.foolcdn.com/editorial/images/760422/people-agreeing-on-a-deal.jpg)
![](https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600.jpg)
![](https://g.foolcdn.com/editorial/images/760970/solar-panels-and-workers.jpg)
![](https://g.foolcdn.com/editorial/images/760878/gettyimages-three-business-people-use-tablets.jpg)
![](https://g.foolcdn.com/editorial/images/761087/gettyimages-904880170.jpg)
![](https://g.foolcdn.com/editorial/images/760285/patient-sitting-on-hospital-bed.jpg)
2 Red Flags for Bluebird Bio Stock
January 10, 2024
Via The Motley Fool
![](https://g.foolcdn.com/editorial/images/760656/gettyimages-936284004.jpg)
![](https://g.foolcdn.com/editorial/images/760286/gettyimages-519517489-1.jpg)
![](https://g.foolcdn.com/editorial/images/759047/gettyimages-2024-stocks-chart.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.